[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
November 7, 2001

Safety Assessment of DEHP

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;286(17):2085. doi:10.1001/jama.286.17.2085-JFD10010-2-1

The FDA has assessed the safety of patients undergoing certain medical procedures (such as blood transfusion, intravenous infusion of crystalloid fluids and drugs, hemodialysis, peritoneal dialysis, total parenteral nutrition, enteral nutrition, and cardiopulmonary bypass) involving exposure to di-(2-ethylhexyl) phthalate (DEHP), a compound used as a plasticizer for polyvinyl choloride medical devices.

The agency concluded that there is little risk of DEHP-mediated effects in adults receiving intravenous solutions or undergoing peritoneal dialysis. However, the results of studies in young animals have suggested that prolonged exposure of male neonates to devices that release DEHP may affect the development of their testes and normal spermatogenesis. The full assessment is available at http://www.fda.gov/cdrh/ost/dehp-pvc.pdf.

First Page Preview View Large
First page PDF preview
First page PDF preview
×